Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2020

Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors

20201221 – CTA Approval BT-001 – EN

Published 21 December 2020
Categorized as 2020, BT-001, Invir.IO, Press release

Transgene Announces Financial Calendar for 2021

20191217 Financial calendar 2021 EN

Published 17 December 2020
Categorized as 2020, Press release

Transgene Announces Investor Meetings for January 2021

20201216 PR Investors Meeting agenda Jan 2021

Published 16 December 2020
Categorized as 2020, Press release

Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020

20201203 – TG4001 mini oral prez ESMO IO EN

Published 3 December 2020
Categorized as 2020, Press release, TG4001, TG4001

Transgene appoints Hedi Ben Brahim as Chairman and Chief Executive Officer

20201203 – Nomination Transgene – EN

Published 3 December 2020
Categorized as 2020, Press release

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators

Franck Gallardo, et al. Biomedicines, November 26 2020 – Read the article Publication

Published 26 November 2020
Categorized as -others, 2020, Invir.IO, Publication

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators

Franck Gallardo, et al. Biomedicines, November 26 2020 – Read the article Publication

Published 26 November 2020
Categorized as -others, 2020, Invir.IO, Publication

TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity

Poster SITC TG4001 C. Le Tourneau et al. SITC 2020 Download the poster here Poster Presentation

Published 9 November 2020
Categorized as -others, 2020, Publication, TG4001

TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity

Poster SITC TG4001 C. Le Tourneau et al. SITC 2020 Download the poster here Poster Presentation

Published 9 November 2020
Categorized as -others, 2020, Publication, TG4001

BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment

Poster BT-001 M. Semmrich et al. SITC 2020 Download the poster here Poster Presentation

Published 9 November 2020
Categorized as -others, 2020, BT-001, Publication

Posts pagination

Page 1 … Page 5 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu